Nektar Therapeutics (NKTR) Tops Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $63.22 -0.68%
EPS Growth %: +26.6%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: +26.6%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $58.9 million versus the consensus estimate of $43.78 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- InTest joins Russell 2000 and Russell 3000 indexes
- BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
